
SAGE Therapeutics Inc
NASDAQ:SAGE

Intrinsic Value
The intrinsic value of one
SAGE
stock under the Base Case scenario is
18.65
USD.
Compared to the current market price of 6.53 USD,
SAGE Therapeutics Inc
is
Undervalued by 65%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
SAGE Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
SAGE Therapeutics Inc
Balance Sheet Decomposition
SAGE Therapeutics Inc
Current Assets | 454.5m |
Cash & Short-Term Investments | 423.9m |
Receivables | 13.4m |
Other Current Assets | 17.2m |
Non-Current Assets | 15.2m |
PP&E | 11.1m |
Other Non-Current Assets | 4.1m |
Free Cash Flow Analysis
SAGE Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
SAGE Therapeutics Inc
Revenue
|
47.4m
USD
|
Cost of Revenue
|
-8.8m
USD
|
Gross Profit
|
38.6m
USD
|
Operating Expenses
|
-398.4m
USD
|
Operating Income
|
-359.8m
USD
|
Other Expenses
|
5.4m
USD
|
Net Income
|
-354.4m
USD
|
SAGE Profitability Score
Profitability Due Diligence
SAGE Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Score
SAGE Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
SAGE Solvency Score
Solvency Due Diligence
SAGE Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
SAGE Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SAGE Price Targets Summary
SAGE Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
SAGE
is 8.21 USD
with a low forecast of 5.05 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for SAGE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
SAGE
stock under the Base Case scenario is
18.65
USD.
Compared to the current market price of 6.53 USD,
SAGE Therapeutics Inc
is
Undervalued by 65%.